Matthew Phelan
Research Subjects
Matthew Phelan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Breskin
Regeneron Pharmaceuticals, Inc., Tarrytown, USA
10 shared publications - Anju Shrestha
Regeneron Pharmaceuticals, Inc. 2 Tarrytown, New York
10 shared publications - Attaya Suvannasankha
Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
10 shared publications - Christian Hampp
Regeneron Pharmaceuticals Inc., Tarrytown, USA
10 shared publications - Daniel Lee
Regeneron Pharmaceuticals, Inc. 2 Tarrytown, New York
10 shared publications - Glenn S. Kroog
Regeneron Pharmaceuticals Inc., Tarrytown, USA
10 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose:This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma who received chimeric antigen receptor T-cell (CAR T) therapy versus other systemic anticancer therapies (SACT). Experimental Design:Adult patients with multiple myeloma who initiated CAR T therapy or other SACT were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values were calculated for the difference between 0 and 24 months. Results:The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACT (median follow-up, 11.8 months). Compared with other SACT, CAR T therapy was associated with similar risks of any SPM (at 24 months, 24.1% vs. 22.3%; P0–24 months = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 months = 0.32) but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 months = 0.04). In a sensitivity analysis requiring ≥ 2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 months = 0.08). Notably, bone marrow examinations were more common after CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions:In this real-world dataset with relatively short follow-up, patients with multiple myeloma seemed to have a higher risk of hematologic SPM after CAR T therapy compared with other SACT. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose:This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma who received chimeric antigen receptor T-cell (CAR T) therapy versus other systemic anticancer therapies (SACT). Experimental Design:Adult patients with multiple myeloma who initiated CAR T therapy or other SACT were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values were calculated for the difference between 0 and 24 months. Results:The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACT (median follow-up, 11.8 months). Compared with other SACT, CAR T therapy was associated with similar risks of any SPM (at 24 months, 24.1% vs. 22.3%; P0–24 months = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 months = 0.32) but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 months = 0.04). In a sensitivity analysis requiring ≥ 2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 months = 0.08). Notably, bone marrow examinations were more common after CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions:In this real-world dataset with relatively short follow-up, patients with multiple myeloma seemed to have a higher risk of hematologic SPM after CAR T therapy compared with other SACT. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S1. Attrition of patients with multiple myeloma and their index treatment periods with CAR T therapy and other SACT LoT
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S1. Attrition of patients with multiple myeloma and their index treatment periods with CAR T therapy and other SACT LoT
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S3. Unweighted proportions of patients with multiple myeloma who received blood smear and bone marrow aspiration/biopsy before and following treatment with individual CAR T therapies
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S3. Unweighted proportions of patients with multiple myeloma who received blood smear and bone marrow aspiration/biopsy before and following treatment with individual CAR T therapies
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S2. Weighted incidence rate (95% CI) of specific types of solid SPM (left) and hematologic SPM (right) in patients with multiple myeloma receiving CAR T therapy or other SACT in the main analysis
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Figure S2. Weighted incidence rate (95% CI) of specific types of solid SPM (left) and hematologic SPM (right) in patients with multiple myeloma receiving CAR T therapy or other SACT in the main analysis
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S1. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT, main analysis and sensitivity analyses
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S1. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT, main analysis and sensitivity analyses
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S2. Weighted cumulative incidence of SPM with death as a censoring criterion in patients with multiple myeloma receiving CAR T therapy or other SACT
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S2. Weighted cumulative incidence of SPM with death as a censoring criterion in patients with multiple myeloma receiving CAR T therapy or other SACT
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S3. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT and remained at-risk at Month 2, stratified by receipt of post-baseline bone marrow examinations by Month 2
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S3. Weighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving CAR T therapy or other SACT and remained at-risk at Month 2, stratified by receipt of post-baseline bone marrow examinations by Month 2
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S4. Unweighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving individual CAR T therapies
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Table S4. Unweighted cumulative incidence of SPM with death as competing risk in patients with multiple myeloma receiving individual CAR T therapies
- Open Access
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4178-4187
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma (MM) who received CAR T therapy versus other systemic anticancer therapies (SACTs). Patients and Methods: Adult patients with MM who initiated CAR T therapy or other SACTs were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values calculated for difference between 0 and 24 months. Results: The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACTs (median follow-up: 11.8 months). Compared with other SACTs, CAR T therapy was associated with similar risks of any SPM (at 24 months: 24.1% vs. 22.3%,P0–24 mo’s = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 mo’s = 0.32), but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 mo’s = 0.04). In a sensitivity analysis requiring ≥2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 mo’s = 0.08). Notably, bone marrow examinations were more common following CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions: In this real-world dataset with relatively short follow-up, patients with MM appeared to have a higher risk of hematologic SPM following CAR T therapy compared with other SACTs. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.
- 12 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4178-4187
Open AccessSecond Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study
Purpose: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma (MM) who received CAR T therapy versus other systemic anticancer therapies (SACTs). Patients and Methods: Adult patients with MM who initiated CAR T therapy or other SACTs were identified from Komodo Health claims data and weighted to balance baseline characteristics. Cumulative incidence of SPM was estimated over 24 months, and P values calculated for difference between 0 and 24 months. Results: The study included 435 patients who received CAR T therapy and 12,268 patients who received other SACTs (median follow-up: 11.8 months). Compared with other SACTs, CAR T therapy was associated with similar risks of any SPM (at 24 months: 24.1% vs. 22.3%,P0–24 mo’s = 0.31) and solid SPM (9.1% vs. 11.5%, P0–24 mo’s = 0.32), but significantly higher risk of hematologic SPM (17.9% vs. 13.1%, P0–24 mo’s = 0.04). In a sensitivity analysis requiring ≥2 claims to identify an SPM, difference in hematologic SPM risk was attenuated (5.5% vs. 4.9%, P0–24 mo’s = 0.08). Notably, bone marrow examinations were more common following CAR T therapy (e.g., 47% vs. 13% at 0–3 months). Conclusions: In this real-world dataset with relatively short follow-up, patients with MM appeared to have a higher risk of hematologic SPM following CAR T therapy compared with other SACTs. However, misclassification and detection bias cannot be ruled out. The association warrants further evaluation. Physicians should be vigilant for myeloid malignancies after CAR T therapy.